Antitumor drug CR 173487

CR 173487 is a new highly effective drug for malignant tumours treatment with the following properties:

• CR 173487 has the unique ability to destroy selectively only malignant tumors cells exclusively without affecting healthy cells in the human body
• CR 173487 is effective for malignant tumors of various localizations, histogenesis and cytogenesis
• CR 173487 participates in the regulation of both the holistic physiological system of the body connected with the DNA molecular stability as a whole and, at different levels of vital functions of the body; it participates in the regulation at cells and tissues levels

Based on the existing clinical experience, high effectiveness of the drug in the treatment of malignant tumors is observed including the treatment of the following malignancies:

It should be noted that:

Cases of effective drug action in treatment of incurable forms of malignant tumors of other localizations have been recorded as well.

 The Principles of the  Drug Action

CR 173487 has been created on the basis of the biologically active substance, due to which the drug has a number of structural peculiarities, which ensure the uniqueness of its biophysical and biochemical characteristics.

The drug can be considered as a bionic solution to the problem of cellular and humoral regulation of the body functions found using the basic principles of the theory of resolution of invention-related tasks (TRIZ). It means that the contradiction between the specificity of the action of the drug and the therapeutic latitude in natural system of the enzymatic cascades non-specific resistance and in drug CR 173487 is resolved in analogies ways.

The avalanche-like tumor cells destruction occurs during treatment with the drug. As a result, in the process of the mechanisms study of the drug action the following peculiarities have been determined:

• the possibility of fine resonance adjustment/tuning of the drug structure to different cell receptor complexes
• effective preservation of the found resonance adjustment after binding to the corresponding receptor complex
• the presence of lipophilic aromatic nucleus and two amphiphilia lateral radicals provides the ability of the drug molecule to stimulate hydrophilic and lipophilic (such as Cytochrome-450 and its isoforms) cell receptors, which determines the possibility of adaptive embedding of the drug molecules in the system of phonopic regulation of the genome functions
• the drug freely passes the blood-brain barrier

These physical and chemical properties of the drug ensure its ability to differentially regulate genomic and epigenomic processes at different levels:

• at the level of receptor fields stimulation and co-stimulation
• at the level of enzyme activity direct regulation
• at the level of direct or indirect individual genes expression regulation and regulation of genes complexes

The results of clinical studies that have already been conducted demonstrate high potential of the drug for cancer treatment including incurable cases.

Therapeutic concentration of the drug in the body is reached within 30-40 minutes after the injection and is maintained from a few days to several months, as long as the body has a significant number of genetically modified cells. With the introduction of the optimal therapeutic dose, the destruction of tumour cells in the patient’s body is completed in 15-20 days.

Study of the biological action of the drug (cytomorphological study) shows that cell death as the action of the drug in all cases occurs both in the type of apoptosis and by the type of autophagic degeneration. The results of anticancer activity studies confirm the pronounced cytotoxic and antitumor activity of the drug.

Studies and Trials of the Drug

Studies and trials of drug CR 173487 have been carried out in the leading research institutes of Ukraine and in medical institutions and on such parameters as tolerance, safety, therapeutic action, pharmacokinetic and pharmacodynamic characteristics, therapeutic dosage levels, and study of ways of its administration, development of treatment protocols according to the diagnosis has been made as well.

Phase I of clinical studies, 2007- 2009

The studies allowed for preliminary conclusions on anticancer activity of the drug as to:

• clinical inhibition of the tumour process
• process of therapeutic pathomorphosis
• the ability to improve of quality of life

Since 2018, clinical trials of the drug have been carried out on a number of the following aggressive tumours:

Due to advanced research conducted during the clinical trials, Phase I, the following parameters were recorded and approved:

• maximum allowable doses of the drug (tolerance)
• dosage of drugs necessary for the treatment of a particular cancer type
• the method of administration of the drug (form of use)

Phase II of Clinical Trials

Phase II of controlled randomized clinical trials showed high effectiveness of the drug and allowed to draw up preliminary treatment protocols depending on the diagnosis and other important indicators.

Based on the results of the trials, it is possible to draw the following preliminary conclusions about the anticancer activity of the drug: clinical inhibition of the tumour process has been established, which indicates in favour of therapeutic pathomorphosis and is resulted in improvement in the quality of life (according to WHO questionnaires). No addiction to the drug is defined.

Phase III of Multicenter Clinical Trials for a Number of Malignant Tumours

Phase III of clinical trials has been actively conducted since 2017 and it is characterized by positive qualitative results.

 Antitumor Drug CR 173487

The drug is able to put the patient into long-term remission and cure the patient.

Specificity of the Drug Use

Use of the drug can improve health of almost all cancer patients as the destruction of a significant part of tumour cells in the patient’s body occurs during the first two-three weeks after the beginning of the treatment.

The Length of Treatment with the Drug

The length of treatment with the drug including rehabilitation processes (removal and resorption of destroyed cells and restoration of proper functions of the patient’s body) depends on the nature and severity of the disease. For patients weakened by the previous use of highly toxic drugs and procedures and having several areas of cancer, the process of treatment with the drug is longer and is carried out in stages. The specific duration of treatment with the drug, the dose of the drug and the methods of its administration depend on the localization, histogenesis and cytogenesis of the malignant tumour and the presence, location and metastatic formations size.

During treatment with the drug, constant clinical control of the patient’s health is required. It is important to exclude other drugs not agreed to use including alcohol-containing drugs. The drug must not be used simultaneously with radiation and chemotherapy therapy as these methods significantly increase the level of toxic substances in the body, oppress the patient’s immune system, negatively affect the body’s ability to regenerate tissues and levels the effect of the drug.